We can see progress. More neuroendocrine tumor (NET) treatment options are emerging. This year, we saw results from scientific research in the clinic—a new modality of treatment became routinely available in America—peptide receptor radionuclide therapy (PRRT). Other advancements continue down the pipeline bringing us closer to increasing therapeutic options in NET care. (MORE)

In 2018, FDA approved PRRT using Lutetium 177 dotatate to treat gastrointestinal and pancreatic NETs. NETRF is already pursuing advancements in the laboratory to increase PRRT's effectiveness and working to increase the number of people who may benefit from it. (MORE)

Your gifts enable us to fund the most promising research on innovative treatment options for neuroendocrine cancers. 

NETRF seeks out world-class researchers around the globe. Four of our NETRF-funded researchers and a 2018 member of our Board of Scientific Advisors were named in the top 1% of their fields worldwide for 2018. (MORE)

Through hosting and co-sponsoring regional NET conferences for patients and caregivers, we are reaching more and more people where they live to offer information and insights about NET testing and treatments. 

The internet is the main source of health information for many. Yet reliable, accurate information on NETs is still hard to find. NETRF offers comprehensive information and resources for those facing a NET diagnosis.